Skip to main content
Oxurion NV logo

Oxurion NV — Investor Relations & Filings

Ticker · OXUR ISIN · BE0974487192 LEI · 549300VWY8KVDFKLDM59 BR Professional, scientific and technical activities
Open in API
Filings indexed 1,031 across all filing types
Latest filing 2023-11-20 Regulatory Filings
Country BE Belgium
Listing BR OXUR

About Oxurion NV

https://oxurion.com/

Oxurion NV is a company focused on acquiring majority stakes in European pharmaceutical subcontractors. Its strategy is to build an integrated group of contract service providers to support healthcare stakeholders. A key asset in its portfolio is a majority stake in Axiodis CRO, a contract research organization specializing in biometrics. This investment-based business model represents a strategic pivot from the company's former focus on the internal research and development of therapies for retinal diseases such as Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD).

Recent filings

Filing Released Lang Actions
Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema ENG.pdf
Regulatory Filings Classification · 95% confidence The document is a press release from Oxurion NV announcing negative clinical trial results (KALAHARI Phase 2, Part B) and the subsequent decision to file for bankruptcy. While it contains significant corporate news, it does not fit into specific categories like '10-K' (annual report), 'CT' (transcript), or 'ER' (earnings release). It is a regulatory announcement regarding material inside information. Given the 'Menu vs Meal' rule, although it contains an attachment link, the content itself is a substantive announcement of a material event (bankruptcy filing due to trial failure), making 'RNS' (Regulatory Filings) the most appropriate classification for this type of corporate disclosure.
2023-11-20 English
KALAHARI Nov 2023 Update.pdf
Regulatory Filings Classification · 95% confidence The document is explicitly titled as a "PRESS RELEASE" and contains "Regulated information – Inside information." It announces the topline data from a clinical trial (KALAHARI Phase 2, Part B) and, critically, states that the Board has decided to file for bankruptcy. This type of immediate, material, non-periodic disclosure, especially one involving significant corporate action (bankruptcy filing) and clinical trial results, is typically disseminated via a press release. Since it is an initial announcement of results and a major corporate event, it fits best as an Earnings Release (ER) if it were quarterly results, but since it's a specific clinical/corporate event announcement, and not a full report (like 10-K or IR), the most appropriate general category for a material, non-periodic announcement that isn't a standard financial report or a specific insider trade/dividend notice is often the Earnings Release category if it contains key performance indicators, or the general Regulatory Filings (RNS) if it's purely regulatory. Given the content focuses on clinical trial results and the subsequent bankruptcy decision, it functions as a major corporate update. However, the definitions provided do not have a specific 'Clinical Trial Result Announcement' or 'Bankruptcy Filing Announcement'. It is not a Call Transcript (CT), not a full Annual Report (10-K), nor an Interim Report (IR). It is an initial release of key data and a major corporate decision. In the context of the provided codes, 'ER' (Earnings Release) is often used broadly for initial results announcements, but 'RNS' (Regulatory Filings) is the fallback for general regulatory announcements. Since this is a highly material, time-sensitive announcement of clinical data and a bankruptcy decision, which must be disclosed immediately, it aligns closely with the function of an Earnings Release (announcing key performance metrics/outcomes) or a general Regulatory Filing. Given the structure and purpose (announcing key data points and a major corporate decision), 'ER' is a strong candidate if we interpret it as the release of 'results'. However, since it is not explicitly quarterly earnings, 'RNS' (Regulatory Filings) serves as the best fit for a mandatory, material disclosure that doesn't fit the other specific financial report codes.
2023-11-20 English
KALAHARI Nov 2023 Update (NL).pdf
Legal Proceedings Report Classification · 99% confidence The document is explicitly titled and formatted as a "PERSBERICHT" (Press Release) and contains "Gereglementeerde informatie – Voorwetenschap" (Regulated Information – Inside Information). It announces the topline data results from a clinical trial (KALAHARI phase 2, part B) for a drug (THR-149) and immediately follows this news with the decision by the Board to file for bankruptcy. This structure—a formal announcement of material, non-public information regarding clinical trial results and subsequent corporate action—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on the immediate release of key financial/operational results (clinical trial outcome) rather than a comprehensive periodic report (like 10-K or IR), 'ER' is a strong candidate. However, given the nature of the announcement (clinical trial results and bankruptcy filing) which is material information released outside of standard quarterly reporting cycles, and the explicit use of 'PERSBERICHT', it fits best as an 'ER' (Earnings Release, often used broadly for key results announcements) or 'RNS' (Regulatory Filing). Since it contains the core results and the immediate consequence, 'ER' is slightly more specific than the general 'RNS'. The document length (10217 chars) is substantial, indicating it is the primary announcement, not just a notice of publication (RPA). I will classify it as an Earnings Release (ER) as it details the key performance indicator (clinical trial result) that triggered the major corporate action.
2023-11-20 Dutch
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas" and explicitly states it is a "Regulated Information - Denominator" update. It details a capital increase resulting from the conversion of convertible bonds and provides the updated total number of shares carrying voting rights (the denominator). This type of mandatory disclosure, which directly impacts the calculation of shareholdings and voting power, is a specific type of regulatory announcement concerning capital structure and voting rights. While it relates to capital changes (CAP) and share structure (SHA), the primary focus is the mandatory disclosure of the new total voting rights count, which aligns closely with notifications regarding share ownership thresholds or capital structure changes that affect voting rights. Given the options, this is a specific regulatory filing related to the capital structure and voting rights denominator. It is not a general earnings release (ER), a full annual report (10-K), or a proxy statement (PSI). Since it is a mandatory disclosure updating the denominator for shareholding calculations, it fits best under a general regulatory filing category or one related to capital/share changes. However, the core function is announcing the new denominator, which is often required under major participation disclosure rules (as cited: Belgian Act of May 2, 2007). This is a specific regulatory disclosure that doesn't perfectly match the defined categories like DIV, SHA, or MRQ, but it is a formal regulatory update. Given the context of updating the total number of voting rights, which is a key component of major shareholding notifications (MRQ) or general regulatory updates (RNS), RNS is the safest fallback for specific regulatory disclosures not explicitly covered. However, since it involves a capital increase and the resulting share count, it is closely related to capital structure changes. Let's re-evaluate the options: It is not a DVA (Declaration of Voting Results), but rather a denominator update. It is not a SHA (Share Issue/Capital Change) in the sense of announcing a new offering, but rather the *result* of a conversion. It is a mandatory disclosure under Belgian law. The closest fit among the specific options is often RNS for mandatory, non-standard disclosures. However, the document explicitly details the change in the total number of securities with voting rights, which is a key component of major shareholding notifications (MRQ) or general capital structure updates. Since the document is a formal, mandatory disclosure updating the denominator used for calculating ownership percentages, and it is not a general announcement of a report (RPA), RNS is the most appropriate general regulatory filing category for this specific type of mandatory disclosure that doesn't fit perfectly elsewhere.
2023-11-19 English
oxur-pr-voting-rights-ned-20231119.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie" (Information regarding the Total Number of Voting Rights (Denominator) following Atlas Conversion Notice). It explicitly states that it is disclosing information pursuant to Article 15 of the Belgian law concerning the disclosure of major shareholdings, and it details the change in the total number of outstanding shares (the denominator) from 3,247,913,079 to 3,489,458,972 following a capital increase via convertible bond conversion. This type of mandatory disclosure, focusing specifically on the total number of voting rights (the denominator) after a capital event, aligns most closely with notifications related to significant share ownership changes or capital structure updates that impact voting power. While it relates to capital changes (CAP), the primary focus and regulatory trigger mentioned (Article 15, disclosure of major shareholdings/voting rights) strongly suggest a notification about shareholding thresholds or voting rights calculation basis. Among the provided codes, 'Major Shareholding Notification' (MRQ) is the closest fit for documents detailing changes to the total share count used as the denominator for ownership calculations, as these notifications are often triggered by crossing ownership thresholds or significant capital events affecting the total share base. It is a regulatory announcement, but MRQ is more specific than RNS or RPA.
2023-11-19 Dutch
OXUR PR_Voting rights (ENG)_20231116.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled as a "PRESS RELEASE" and falls under "Regulated Information - Denominator". The core content announces the "Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas". This announcement details a capital increase resulting from convertible bond conversion and updates the total number of outstanding ordinary shares carrying voting rights (the denominator). This type of mandatory disclosure regarding changes in the total number of voting rights, often triggered by capital structure events like bond conversions or share issuances, is a specific regulatory filing requirement in many jurisdictions (referenced here by the Belgian Act). While it relates to capital changes (CAP) and share issuance (SHA), the specific focus on updating the official denominator for shareholder voting calculations strongly aligns with mandatory regulatory disclosure, often categorized under general regulatory announcements or specific voting-related disclosures. Given the options, this is a mandatory regulatory disclosure concerning the capital structure and voting rights base. It is not an Earnings Release (ER), Interim Report (IR), or a general management discussion (MDA). Since it is a specific regulatory update about the number of shares used for voting calculations, it fits best under the general "Regulatory Filings" (RNS) as a specific type of required disclosure, or potentially related to voting rights (DVA), but DVA is for *results* of votes. Since it is a mandatory disclosure of the total share count used as the denominator, RNS is the most appropriate general regulatory fallback for this specific type of mandatory update that isn't covered by the other specific codes.
2023-11-16 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.